Our vision is to improve the treatment of severe diseases in order to provide benefits for both patients and society as a whole.

About Oasmia

Read more about our XR17 technology

Read more

the share

%

research

production

investor information

veterinary health division

news

Oasmia Pharmaceutical Secures Financing of 108 MSEK

Oasmia Pharmaceutical AB (publ) (“Oasmia” or the ”Company”) a developer of a new generation of drugs within human and veterinary oncology, has agreed to a loan totalling 108 million SEK, of w...
Read more

Oasmia Pharmaceutical receives marketing approval for Paclical® in Kazakhstan

Oasmia Pharmaceutical AB (NASDAQ: OASM), a developer of a new generation of drugs within human and veterinary oncology, announced today that it has received marketing approval for Paclical in Kazakhst...
Read more

Oasmia has completed a private placement of new convertible instruments in a total amount of SEK 28,000,000

Oasmia Pharmaceutical AB (publ) (“Oasmia” or the “Company”) hereby announces that the Company has completed a private placement of a convertible loan in the amount of SEK 28,000,000 with an in...
Read more